Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

Lunchtime Update, Biotech Movers

Market had a nice little bounce off the early lows of the day, especially the Nasdaq before recent trading action took that index back to flat for the day, and now down again. Biotech really looks like it is trying to put in a bottom and rally. Toda...

A Bright Spot Amid Broad-Based Declines and a Story to Watch

The market opens lower as pre-market futures were pointing to. Equities are off the worst levels of the day. After taking on some gas in trading yesterday, the SPDR S&P Biotech ETF  is a bit in the green today despite all the major indexes being sig...

2 Stocks That Look Promising for 2022 and Are Seeing Big Insider Buys to Boot

Thor Industries and Six Flags Entertainment are attracting insider attention.

Eye on Skyworks, a Potential Acquisition and Omicron

Looks like we are going to open the last day of what has been a miserable week for the markets in the red, based on where futures are currently trading. Small-caps, once again, look like they will take the brunt of the early decline. Skyworks Soluti...

Now at the Plate, Your Pinch Hitter, Bret Jensen

I'm Bret Jensen, and I am happy to be sitting in on the Daily Diary for Doug Kass this Friday. Let's hope we can end another challenging week in the markets on an up note. I am sure there will be lots of investment topics today. Here are a few I wil...

The Bedraggled Biotech Sector Finally Offers a Glimmer of Hope

Two recent acquisition deals and big drug companies that are flush with cash provide reason to believe biotech stocks could rebound in 2022

Omicron's Threat Isn't What We Thought It Was, but Inflation Sure Is

And it doesn't appear the high level of inflation consumers are experiencing is going to abate any time soon.

Options Play of the Week: A Trade to Shoot for Monday

Smith & Wesson's recent selloff was an overreaction. Here's how to take advantage of it.

As Inflation Soars, Here's One Stock to Add to Your Portfolio

I've scooped up shares of giant phosphate and potash concern Mosaic.

Has the January Effect Commenced?

This could be the start of nice rally in the beaten-down parts of the market, but here's why I am not chasing it.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight